Rapport Therapeutics (RAPP) Non-Current Assets (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Non-Current Assets of $12.9 million for Q1 2026, up 16.39% year-over-year from $11.1 million in Q1 2025, and down 6.98% quarter-over-quarter from $13.9 million in Q4 2025.
Rapport Therapeutics (RAPP) Non-Current Assets (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Non-Current Assets for 4 consecutive years, with $12.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 16.39% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $56.7 million (up 111.11% YoY), while the FY2025 annual figure was $13.9 million, up 170.32% from the prior year.
- Non-Current Assets slipped to $12.9 million in Q1 2026 per RAPP's latest filing, from $13.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $15.3 million in Q2 2025 and bottomed at $4.6 million in Q4 2023.
- Historically, Non-Current Assets has averaged $9.8 million across 4 years, with a median of $11.1 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Assets gained 12.74% — and 2025, when it soared 181.73%.
- Rapport Therapeutics' Non-Current Assets stood at $4.6 million in 2023, then advanced by 12.74% to $5.1 million in 2024, then soared by 170.32% to $13.9 million in 2025, then dropped by 6.98% to $12.9 million in 2026.
- Business Quant data shows RAPP's Non-Current Assets at $12.9 million in Q1 2026, $13.9 million in Q4 2025, and $14.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.13 Mn |
| Mar 31, 2026 | 12.90 Mn |
| Dec 31, 2025 | 13.87 Mn |
| Sep 30, 2025 | 14.66 Mn |
| Jun 30, 2025 | 15.25 Mn |
| Mar 31, 2025 | 11.09 Mn |
| Dec 31, 2024 | 5.13 Mn |
| Sep 30, 2024 | 5.21 Mn |
| Jun 30, 2024 | 5.43 Mn |
| Dec 31, 2023 | 4.55 Mn |